IL23A and inflammatory bowel disease 5: Data supporting the critical pathogenic role of IL-23 in inflammatory diseases has led to development of therapies that inhibit the IL-23 pathway and IL-23–targeted biologics have been clinically validated in patient populations with psoriatic skin and joint inflammation and in IBD5,22–25.